A group of Duke Cancer Institute gynecologic oncology researchers has published a new paper this month with their projections on the cost-effectiveness of ovarian cancer screening in the U.S., based on their analysis of published results of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
The DCI group used statistical modeling to tailor the UKCTOCS results — that had concluded that screening might eventually be able to save lives in the U.K — to a U.S. population.
“Ours is the first study to look at the cost-effectiveness implications of screening using the UKCTOCS algorithm in the U.S., where the rate of developing ovarian cancer is about 1.4 percent over a lifetime,” said senior author Laura Havrilesky, MD, MHSc. “Our conclusion is that if proven effective, a screening test would also be potentially cost-effective in the U.S. We found that multimodal screening with serum CA-125, could reduce mortality by 15% (as was found in the U.K. study) with an ICER ranging from $106,187 to $155,256.”